Ticagrelor

Ticagrelor (AZD6140) is a reversible oral P2Y12 receptor antagonist for the treatment of platelet aggregation.

Product Specifications

CAS Number

[274693-27-5]

Product Name Alternative

AZD6140; AR-C 126532XX

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

P2Y Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein

Applications

COVID-19-immunoregulation

Field of Research

Cardiovascular Disease; Cancer

Assay Protocol

https://www.medchemexpress.com/Ticagrelor.html

Purity

99.98

Solubility

DMSO : ≥ 50 mg/mL

Smiles

O[C@H]1[C@@H](O)[C@H](N2N=NC3=C(N[C@H]4[C@H](C5=CC=C(F)C(F)=C5)C4)N=C(SCCC)N=C32)C[C@@H]1OCCO

Molecular Formula

C23H28F2N6O4S

Molecular Weight

522.57

Precautions

H302, H315, H319, H335

References & Citations

[1]Aungraheeta R, et al. Inverse agonism at the P2Y12 receptor and ENT1 transporter blockade contribute to platelet inhibition by ticagrelor. Blood. 2016 Dec 8;128 (23) :2717-2728.|[2]Gebremeskel S, et al. The reversible P2Y12 inhibitor ticagrelor inhibits metastasis and improves survival in mouse models of cancer. Int J Cancer. 2015 Jan 1;136 (1) :234-40.|[3]Sugidachi A, et al. A comparison of the pharmacological profiles of prasugrel and ticagrelor assessed by platelet aggregation, thrombus formation and haemostasis in rats. Br J Pharmacol. 2013 May;169 (1) :82-9.